NCT00025662View on ClinicalTrials.gov

Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Graft vs Host DiseaseMyelodysplastic SyndromesLeukemiaLeukemia, MyeloidLeukemia, Myelomonocytic, ChronicLeukemia, LymphocyticLymphomaLymphoma, Mantle-cellLymphoma, Non-HodgkinHodgkin Disease
Interventions
DRUG

RFT5-SMPT-dgA

A specific anti-interleukin-2 receptor immunotoxin

DRUG

Isolex system

CD34 selection/ T cell depletion used this system

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00025662 - Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | Biotech Hunter | Biotech Hunter